Older women with localized breast cancer: Costs and survival rates increased across two time periods

Health Affairs

Volumn 34, Issue 4, 2015, Pages 592-600

  Feinstein, Aaron J ^a,b   Long, Jessica ^b   Soulos, Pamela R ^b   Ma, Xiaomei ^c   Herrin, Jeph ^b   Frick, Kevin D ^d   Chagpar, Anees B ^b   Krumholz, Harlan M ^c   Yu, James B ^b   Ross, Joseph S ^b   Gross, Cary P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DATA BASE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; PARTIAL MASTECTOMY; SURVIVAL RATE; VERY ELDERLY; AGE; BREAST NEOPLASMS; CANCER REGISTRY; ECONOMICS; KAPLAN MEIER METHOD; MORTALITY; TRENDS; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; MEDICARE; NEOPLASM STAGING; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 84929615808     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1119     Document Type: Article

References (55)

1. Hartman M, Martin A, Lassman D, Catlin A, National Health Expenditure Accounts Team. National health spending in 2013: growth slows, remains in step with the overall economy. Health Aff (Millwood). 2015; 34(1):150-60.
2. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2010;22(8):643-57.
3. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-97.
4. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4(11):643-56.
5. Howard DH. Realigning incentives for developing and pricing new anticancer treatments. JAMA. 2011; 305(22):2347-8.
6. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011; 29(10):1232-5.
7. Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol. 2011;29(3):254-6.
8. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008 [Internet]. Bethesda (MD): National Cancer Institute; 2011 [cited 2015 Feb 19]. Available from: http://seer.cancer.gov/archive/csr/1975_2008/
9. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
10. Bach PB. Costs of cancer care: a view from the Centers for Medicare and Medicaid Services. J Clin Oncol. 2007;25(2):187-90.
11. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
12. CancerProgress.Net [home page on the Internet]. Alexandria (VA): American Society of Clinical Oncology; [cited 2015 Feb 3]. Available from: http://www.cancerprogress.net/
13. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
14. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
15. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25(6):625-33.
16. Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, et al. Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer. J Natl Cancer Inst. 2014; 106(3):dju008.
17. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-104-17.
18. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2003 [Internet]. Bethesda (MD): National Cancer Institute; 2006 [cited 2015 Feb 19]. Available from: http://seer.cancer.gov/archive/csr/1975_2003/
19. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEERMedicare database: applications and limitations. Med Care. 2002; 40(8 Suppl):IV-19-25.
20. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
21. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York (NY): Springer; 2002.
22. To access the Appendix, click on the Appendix link in the box to the right of the article online.
23. Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care. 2009;47(7 Suppl 1):S56-63.
24. Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine JH, Hogan C, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol. 2002;20(12):2869-75.
25. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol. 2004;22(24):4971-8.
26. Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004; 130(11):1269-75.
27. Smith BD, Pan IW, Shih YC, Smith GL, Harris JR, Punglia R, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011;103(10):798-809.
28. Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in feefor-service settings. J Clin Oncol. 2002;20(1):307-16.
29. Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics. 2009;27(3): 199-209.
30. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29(20):2821-6.
31. Bianco R. ATAC ("arimidex," tamoxifen, alone or in combination) trial-anastrozole is superior to tamoxifen as adjuvant treatment in postmenopausal women with early breast cancer. Abstract for: 25th Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Treat. 2002;76(1 Suppl 1):127.
32. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG.Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-42.
33. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9): 733-44.
34. Van den Broek CB, Bastiaannet E, Dekker JW, Portielje JE, de Craen AJ, Elferink MA, et al. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients-a large population-based study from 1990 to 2008. Acta Oncol. 2013;52(5):941-9.
35. López-Tarruella S, Martín M. Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res. 2009;11(2):204.
36. Tobias JS. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Ann Oncol. 2004;15(12): 1738-47.
37. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26(1):44-53.
38. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504-12.
39. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72.
40. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
41. Delaney G. Recent advances in the use of radiotherapy to treat early breast cancer. Curr Opin Obstet Gynecol. 2005;17(1):27-33.
42. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351(9114):1451-67.
43. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18): 1371-88.
44. Philipson T, Eber M, Lakdawalla DN, Corral M, Conti R, Goldman DP. An analysis of whether higher health care spending in the United States versus Europe is "worth it" in the case of cancer. Health Aff (Millwood). 2012;31(4):667-75.
45. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010;363(16):1495-7.
46. Krumholz HM, Gross CP, Peterson ED, Barron HV, Radford MJ, Parsons LS, et al. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. Am Heart J. 2003;146(5):839-47.
47. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22): 2720-6.
48. Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and agebased disparities. Ann Surg Oncol. 2007;14(12):3328-34.
49. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: metaanalysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804): 1707-16.
50. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A costeffectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634-41.
51. Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, et al. The cost of breast cancer screening in the Medicare population. JAMA Intern Med. 2013; 173(3):220-6.
52. Roehrig C, Miller G, Lake C, Bryant J. National health spending by medical condition, 1996-2005. Health Aff (Millwood). 2009;28(2):w358-67. DOI: 10.1377/hlthaff.28.2.w358.
53. Vincent GK, Velkoff VA. The next four decades: the older population in the United States: 2010 to 2050 [Internet].Washington (DC): Census Bureau; 2010 May [cited 2015 Feb 4]. Available from: http://www.census.gov/prod/2010pubs/p25-1138.pdf
54. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol. 2009;27(35): 5868-73.
55. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305(22):2320-6.